Home › Linfoma di Burkitt › Ohio › Cincinnati
Studi clinici su Linfoma di Burkitt a Cincinnati, OH
12 studi su Linfoma di Burkitt cercano partecipanti presso sedi a Cincinnati e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
In reclutamentoFase 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · a 15 mi di distanza
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
In reclutamentoStudio osservazionale
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
In reclutamentoFase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · a 15 mi di distanza
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
In reclutamentoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
In reclutamentoFase 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
In reclutamentoFase 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
In reclutamentoFase 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
In reclutamentoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
In reclutamentoFase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
In reclutamentoFase 1
- University of Cincinnati, Cincinnati
Studi su Linfoma di Burkitt in altre città
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Atlanta, GA12 studi
- Seattle, WA11 studi
- Boston, MA10 studi
- Durham, NC10 studi
- Aurora, CO10 studi
- Los Angeles, CA10 studi
- Kansas City, MO10 studi
Altri studi a Cincinnati
- Cancro del polmone non a piccole cellule35 studi
- Cancro (tutti i tipi)27 studi
- Cancro al seno25 studi
- Insufficienza cardiaca24 studi
- Cancro colorettale21 studi
- Leucemia mieloide acuta20 studi
- Cancro metastatico20 studi
- Cancro ovarico19 studi
- Cancro ai polmoni19 studi
- Obesità19 studi
- Cancro alla prostata18 studi
- Mieloma multiplo17 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.